Randomised, double-blind, multi-centre, placebo-controlled study to evaluate the efficacy of 6-day additional oral moxifloxacin administration 400 mg once a day (qd) after common antibiotic treatment on acute bacterial exacerbation of chronic obstructive pulmonary disease patients.

Trial Profile

Randomised, double-blind, multi-centre, placebo-controlled study to evaluate the efficacy of 6-day additional oral moxifloxacin administration 400 mg once a day (qd) after common antibiotic treatment on acute bacterial exacerbation of chronic obstructive pulmonary disease patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2012

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Bacterial infections
  • Focus Therapeutic Use
  • Acronyms AAABC
  • Most Recent Events

    • 02 Jul 2012 Actual end date (Jul 2012) added as reported by ISRCTN: Current Controlled Trials.
    • 02 Jul 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 22 Jun 2010 Planned end date changed from Jul 2010 to Jul 2012 as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top